Why Are We Still Talking about Ivermectin? Editorial Note on Stone et al. Changes in SpO2 on Room Air for 34 Severe COVID-19 Patients after Ivermectin-Based Combination Treatment
Conflicts of Interest
References
- Stone, J.C.; Nadarkwa, P.; Scheim, D.E.; Dancis, B.M.; Dancis, J.; Gill, M.G.; Aldous, C. Changes in SpO2 on Room Air for 34 Severe COVID-19 Patients after Ivermectin-based Combination Treatment: 62% Normalization within 24 hours. Biologics 2022, 2, 15. [Google Scholar] [CrossRef]
- Bramante, C.T.; Huling, J.D.; Tignanelli, C.J.; Buse, J.B.; Liebovitz, D.M.; Nicklas, J.M.; Cohen, K.; Puskarich, M.A.; Belani, H.K.; Proper, J.L.; et al. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for COVID-19. N. Engl. J. Med. 2022, 387, 599–610. [Google Scholar] [CrossRef]
- Reis, G.; Silva, E.; Silva, D.C.M.; Thabane, L.; Milagres, A.C.; Ferreira, T.S.; Dos Santos, C.V.Q.; Campos, V.H.S.; Nogueira, A.M.R.; de Almeida, A.; et al. Effect of Early Treatment with Ivermectin among Patients with COVID-19. N. Engl. J. Med. 2022, 386, 1721–1731. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization. Therapeutics and COVID-19: Living Guideline. Available online: https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.4 (accessed on 18 August 2022).
- Abdool Karim, S.S.; Devnarain, N. Time to Stop Using Ineffective COVID-19 Drugs. N. Engl. J. Med. 2022, 387, 654–655. [Google Scholar] [CrossRef]
- Lim, S.C.L.; Hor, C.P.; Tay, K.H.; Mat Jelani, A.; Tan, W.H.; Ker, H.B.; Chow, T.S.; Zaid, M.; Cheah, W.K.; Lim, H.H.; et al. Efficacy of Ivermectin Treatment on Disease Progression among Adults with Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial. JAMA Intern. Med. 2022, 182, 426–435. [Google Scholar] [CrossRef] [PubMed]
- Shafiee, A.; Teymouri Athar, M.M.; Kohandel Gargari, O.; Jafarabady, K.; Siahvoshi, S.; Mozhgani, S.H. Ivermectin under scrutiny: A systematic review and meta-analysis of efficacy and possible sources of controversies in COVID-19 patients. Virol. J. 2022, 19, 102. [Google Scholar] [CrossRef] [PubMed]
- Okumus, N.; Demirturk, N.; Cetinkaya, R.A.; Guner, R.; Avci, I.Y.; Orhan, S.; Konya, P.; Saylan, B.; Karalezli, A.; Yamanel, L.; et al. Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. BMC Infect. Dis. 2021, 21, 411. [Google Scholar] [CrossRef] [PubMed]
- Mahmud, R.; Rahman, M.M.; Alam, I.; Ahmed, K.G.U.; Kabir, A.; Sayeed, S.; Rassel, M.A.; Monayem, F.B.; Islam, M.S.; Islam, M.M.; et al. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: A randomized trial. J. Int. Med. Res. 2021, 49, 3000605211013550. [Google Scholar] [CrossRef] [PubMed]
- Babalola, O.E.; Ndanusa, Y.A.; Ajayi, A.A.; Ogedengbe, J.O.; Thairu, Y.; Omede, O. A Randomized Controlled Trial of Ivermectin Monotherapy versus Hydroxychloroquine, Ivermectin, and Azithromycin Combination Therapy in COVID-19 Patients in Nigeria. J. Infect. Dis. Epidemiol. 2021, 7. [Google Scholar] [CrossRef]
- Omede, O.; Ogedengbe, J.O.; Ndanusa, Y.; Ajayi, A.A.; Babalola, O.E.; Thairu, Y. A Comparison of Ivermectin and Non Ivermectin Based Regimen for COVID-19 in Abuja: Effects on Virus Clearance, Days-to-discharge and Mortality. J. Phar. Res. Int. 2022, 1–19. [Google Scholar] [CrossRef]
- Babalola, O.E.; Ajayi, A.A.; Thairu, Y.; Ndanusa, Y.A.; Ogedengbe, J.O.; Omede, O. Ivermectin is Associated with Increase in SpO2 in Hypoxemic SARS-CoV-2 Patients: Pharmacodynamic Profile and Correlates. J. Clin. Chem. Lab. Med. 2022, 5, 1–9. [Google Scholar] [CrossRef]
- Ahmed, S.; Karim, M.M.; Ross, A.G.; Hossain, M.S.; Clemens, J.D.; Sumiya, M.K.; Phru, C.S.; Rahman, M.; Zaman, K.; Somani, J.; et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int. J. Infect. Dis. 2021, 103, 214–216. [Google Scholar] [CrossRef] [PubMed]
- Caly, L.; Druce, J.D.; Catton, M.G.; Jans, D.A.; Wagstaff, K.M. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir. Res. 2020, 178, 104787. [Google Scholar] [CrossRef] [PubMed]
- French, M.A. HIV/AIDS: Immune reconstitution inflammatory syndrome: A reappraisal. Clin. Infect. Dis. 2009, 48, 101–107. [Google Scholar] [CrossRef] [PubMed]
- Butler, T. The Jarisch-Herxheimer Reaction after Antibiotic Treatment of Spirochetal Infections: A Review of Recent Cases and Our Understanding of Pathogenesis. Am. J. Trop. Med. Hyg. 2017, 96, 46–52. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pincus, S.H. Why Are We Still Talking about Ivermectin? Editorial Note on Stone et al. Changes in SpO2 on Room Air for 34 Severe COVID-19 Patients after Ivermectin-Based Combination Treatment. Biologics 2022, 2, 211-212. https://doi.org/10.3390/biologics2030016
Pincus SH. Why Are We Still Talking about Ivermectin? Editorial Note on Stone et al. Changes in SpO2 on Room Air for 34 Severe COVID-19 Patients after Ivermectin-Based Combination Treatment. Biologics. 2022; 2(3):211-212. https://doi.org/10.3390/biologics2030016
Chicago/Turabian StylePincus, Seth H. 2022. "Why Are We Still Talking about Ivermectin? Editorial Note on Stone et al. Changes in SpO2 on Room Air for 34 Severe COVID-19 Patients after Ivermectin-Based Combination Treatment" Biologics 2, no. 3: 211-212. https://doi.org/10.3390/biologics2030016